High expression of hnRNPU or CTCF was also associated with poor survival of patients with breast cancer, colon cancer, glioblastoma, lung cancer, ovarian cancer, or prostate cancer (Additional file 1: Figure S15). Here, CTCF is linked to lung cancer.